Mizuho analyst Irina Koffler raised her price target for Mallinckrodt to $26 citing higher specialty generics estimates and better durability in hospital brands following the company’s Q4 results. The analyst, however, reiterates a Neutral rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.